GlassScriptPhysician profile
Kimberly Vessels
NPI 1437534336
$58,221.20
in general payments reported to CMS, 2019-2025
20 companies · $1,314 in 2025
The $1,314 reported for 2025 was more than what 89% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $26K · 2022: $17K · 2023: $7,040 · 2024: $7,343 · 2025: $1,314.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,250 · Food and Beverage: $3,986 · Travel and Lodging: $3,461.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,250.00 |
| Food and Beverage | $3,986.10 |
| Travel and Lodging | $3,461.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $50,062.11 | 2021-2025 | Lifevest |
| Abbott Laboratories | $3,740.86 | 2021-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems, Jot Dx |
| Janssen Pharmaceuticals, INC | $1,293.27 | 2021-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $933.01 | 2021-2024 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $853.20 | 2021-2025 | Farxiga, Wainua, Brilinta |
| Janssen Scientific Affairs, LLC | $312.58 | 2021-2024 | Xarelto |
| Vital Connect, INC | $167.08 | 2024 | Vitalpatch Rtm |
| Atricure, INC. | $146.19 | 2024 | |
| Abiomed | $136.04 | 2024 | Impella |
| Lexicon Pharmaceuticals, INC. | $120.33 | 2024 | Inpefa |
| United Therapeutics Corporation | $108.11 | 2021 | |
| Medtronic, INC. | $80.96 | 2021-2023 | Reveal Linq |
| Novartis Pharmaceuticals Corporation | $59.36 | 2022-2024 | |
| Allergan, INC. | $55.08 | 2022 | |
| Merck Sharp & Dohme LLC | $51.70 | 2021-2025 | Verquvo |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $26.38 | 2022 | |
| Galderma Laboratories, L.P. | $23.93 | 2022 | |
| Cvrx, INC. | $18.49 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.55 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $15.97 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Vessels listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.